Recurrence is almost inevitable in glioblastoma (GBM) patients even after aggressive multimodal therapies. Most recurrences occur at the resection margin that is outside GBM's contrast-enhancing region (C region) of magnetic resonance imaging (MRI), and always left behind after surgery. Current knowledge about GBM cells outside C region is limited and thus impedes the post-operative therapy. In this study, single cell RNA-sequencing (scRNA-seq) was performed to dissect twelve GBM samples of C regions and outside C regions from four patients. We found a cluster of peculiar GBM cells outside C region different from the GBM cells with typical copy number variations (CNVs), which had only fragmental CNVs in chromosomes 1, 10, 11, 12 and 19, and were termed CNV 4 in this study. Furthermore, transcription factor-cofactor (TF-TCF) interaction network was constructed to uncover the transcriptional regulatory mechanism of GBM cells. The core signature of TF-TCF interaction network of CNV 4 GBM cells shows prognostic significance in GBM patients. Besides, sub-cluster of these peculiar GBM cells possess stem cell-like properties and have potential of tumorigenesis as revealed by in silico and in vitro analyses. To explore whether these peculiar GBM cells exist in the circulation of GBM patients, additional peripheral blood mononuclear cells (PBMC) samples from four GBM patients, three epilepsy patients and three healthy volunteers were analyzed by scRNA-seq. GBM cells were not found in PBMC, but peculiar proliferative immune cells were discovered in the PBMC of GBM patients but epilepsy patients and healthy volunteers. Collectively, these results indicated that peculiar GBM cells 3 outside C region are responsible for recurrence, and proliferative immune cells are specific to the PBMC of GBM patients. This study sheds light on the hidden and neglected parts of GBM, providing a new perspective to understand the nature of GBM recurrence, to develop monitoring strategy or promising immune therapy against GBM.
Introduction
Glioblastoma (GBM), the most common and lethal brain malignancy in adults 1, 2 , is highly heterogeneous and infiltrative. These features lead to the failure of multimodal treatments and subsequent tumor recurrences. GBM is characterized by contrast enhancement in T1-gadolinium enhanced magnetic resonance imaging (MRI) and the surrounding non-enhancing region of abnormal T2-weighted/fluid-attenuated inversion recovery (FLAIR) signal [3] [4] [5] . The former region represents the dense cellular core of GBM with neovascularization and blood-brain barrier (BBB) disruption, which is always resected as much as possible during surgery 5 . The latter region is regarded as edematous tissue with infiltrating GBM cells, part of which is often left behind after surgery, becoming the target of post-operative treatment 5 . Most molecular characterizations of GBM were identified based on the studies of contrast-enhancing samples, and researchers tried efforts to avoid contamination of other brain tissue [6] [7] [8] [9] . However, 90% of GBM recurrences occurred at the resection margin even after total resection of the contrast-enhancing regions 10 . Besides, studies have demonstrated that recurrent GBM cells differed greatly from primary GBM cells in the aspects of genome, transcriptome, and microenvironment 7, [11] [12] [13] . Therefore, knowledge accumulated from the studies of GBM contrast-enhancing regions and therapies developed from this knowledge are insufficient to understand and overcome GBM completely.
On the other hand, more and more studies confirmed that the extent of resection (EOR) is positively associated with superior outcomes of GBM patients. For instance, Yan Michael Li and colleagues showed that additional resection of the surrounding T2/FLAIR abnormality beyond total contrast-enhancing resection prolonged median survival time of GBM patients 14 . In addition, lobectomy of GBM in non-eloquent areas benefited patients in both overall survival (OS) and progression-free survival (PFS) 15 . Furthermore, Hanna Mendes Levitin and colleagues identified GBM cells from the non-enhancing GBM margin, and revealed that the expression signature biased toward infiltrated GBM cells was negatively correlated with patients' survival 16 . These results suggest that the less GBM cells outside the contrast-enhancing region, the better patients will turn out. Meanwhile, these results emphasize the prognostic and therapeutic values to understand the residual GBM cells in more details. Although recent studies are beginning to focus on peri-tumoral region 3, 4, [16] [17] [18] , there are many characteristics of these GBM cells and the underlying regulatory mechanisms remained to be uncovered. 5 In this study, we performed single cell RNA-sequencing (scRNA-seq) on isocitrate dehydrogenase 1-wild type (IDH1-wt) primary GBM. Samples from contrast-enhancing central region (C region), peri-enhancement edematous region (P region), and peri-edema normal region (N region) of four GBM patients were collected separately under the guidance of MRI. For each of these twelve samples, we carried out pathological examination and primary GBM cells culture. Remarkably, we found peculiar GBM cells in P and N regions that might be responsible for recurrence after surgery. To explore whether GBM cells exist in the circulation of GBM patients, additional peripheral blood mononuclear cells (PBMC) samples from four GBM patients, three epilepsy patients and three healthy volunteers were analyzed by scRNA-seq. To our surprise, proliferative immune cells were discovered in the PBMC of GBM patients but epilepsy patients and healthy volunteers.
Results

GBM cells show remarkable heterogeneity at the aspect of CNV
To comprehensively investigate the characteristics of primary IDH-wt GBM, we separately collected samples of C regions, P regions, and N regions from four GBM patients under the guidance of MRI ( Figure 1A , Supplementary Table S1 ).
Hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) staining showed that C regions contained the histological hallmarks of GBM, including microvasculature proliferation and tissue necrosis, as well as high ratio of KI67-positive cells, while P and N regions had no typical GBM features but 6 resembled normal brain tissue in some extent ( Figure S1A, B ). After preparation of single-cell suspension, we profiled these 12 GBM samples and 4 corresponding PBMC samples by using 10×Chromium 3' Single Cell Platform. Totally, 72, 620 cells passed our filters of quality control, including 48, 770 cells from GBM samples and 23, 850 cells from PBMC samples ( Figure 1B, C) . To avoid the disturbance of tissue heterogeneity, GBM samples and PBMC samples were analyzed separately.
All of these cells were classified into malignant cells and non-malignant cells by the following approaches. First, cells were divided into different clusters according to Seurat "FindClusters" function, each of which represented a transcriptome-distinct cell group (Figure 1B, C) . Second, differentially expressed genes (DEGs) of each cluster were identified through comparison to the rest of other clusters. Cell type specific genes in the DEGs were used to inferred the cell identities, and gene ontology (GO) enrichment analysis was performed for further confirmation. According to these approaches, we identified oligodendrocytes, macrophages, T cells and putative GBM cells in GBM samples ( Figure 1B ). T cells, B cells, and monocytes were identified in PBMC samples ( Figure 1C ). For the putative GBM cells that could not be classified as any normal cell types, CNVs were inferred from transcriptomic information by moving average method, which uses 100 genes in each chromosomal region as the moving window to smooth gene-specific expression patterns 8, [19] [20] [21] . This analysis algorithm enabled identification of large-scale amplifications and deletions in putative GBM cells, such as chromosome 7 gain and chromosome 10 loss, which are genetic hallmarks of most GBM cells ( Figure 1D ). proportions ( Figure 2B ). From another perspective, we found that most transcriptomic sub-clusters were derived from multiple CNV patterns ( Figure S2A, B) . In other words, there was no strict correspondence between CNV patterns and transcriptomic sub-clusters, and GBM cells of different CNV patterns resembled with each other at the level of transcriptome in certain extent. We then analyzed the developmental trajectory of these GBM cells to explore their underlying relationship. As shown in Figure 2C , GBM cells of CNV pattern 1 and 4 were located across three states, while CNV patterns 2 and 3 GBM cells were mainly isolated in state 2. Interestingly, the results of pseudo-time suggested potential transitions from CNV pattern 4 to CNV patterns 1, 2, and 3, or from CNV pattern 1 to CNV patterns 2 and 3 ( Figure 2C , Figure S2C ).
Pathway enrichment analysis of DEGs among different states revealed disturbances in many pathways involved in the regulation of gene expression, such as AP1 pathway, glial cell differentiation, regulation of mitotic nuclear division, and canonical Wnt signaling pathway ( Figure 2D ). Notably, 23% of top 100 DEGs belong to transcription factors and transcription cofactors, including SOX2, SOX4, SOX11, ETV1, and CBX3, which played important roles in GBM as demonstrated by previous studies 22-28 ( Figure S2D and Supplemental Table S2 ). Besides, intersection analysis of the DEGs of four CNV patterns showed that only 11 genes were commonly upregulated. Most of the other DEGs were CNV pattern-specific ( Figure 2E ).
Consistently, pathway enrichment analysis of CNV pattern 1-specific DEGs and CNV pattern 4-specific DEGs indicated differences in the transcriptional regulation of gene 9 expression ( Figure S2E , F). Thus, we inferred that CNV patterns and transcriptional regulation cooperated to shape GBM transcriptomic states.
Transcriptional regulatory networks orchestrate transcriptome of GBM cells and correlate with patient outcomes
To investigate the transcriptional regulation of GBM cells, we focused on the transcription factors (TFs) and transcription cofactors (TCFs). Figure 3A described the analysis strategy for TFs-TCFs interaction network construction. Briefly, we firstly picked out TFs and TCFs in DEGs of four CNV patterns respectively. TFs and TCFs cooperate to exert their functions, so we figured out their interaction relationships according to STRING database. To obtain confident interactions, only those derived from curated databases and experiments and with combined scores larger than 0.9 were considered ( Figure S3 , S4, S5, and S6). Sorted by the interaction degree of each TF, top three TFs were chosen as hub TFs for further analysis of differentially expressed target genes and the construction of TF-TCF-Target regulatory networks ( Figure 3B , Figure S7 , S8, S9, S10). We found that JUN played 1 0 differentially expressed TFs and TCFs with fold changes larger than two compared to normal cells. Combining the TFs and TCFs of high interaction degrees and variations, we defined the core TFs and TCFs gene sets for four CNV patterns ( Figure 3C , Figure   S11A ). The sub-networks of core gene sets made up 61.54%, 41.41%, 56.95%, and 58.56% of the whole TF-TCF interaction networks of four CNV patterns, respectively ( Figure S3 , S4, S5, and S6).
These CNV-specific core gene sets were derived from scRNA-seq of only four GBM patients, so we asked whether they were applicable in larger cohort. We found that these gene sets were also highly expressed in GBM tissue of The Cancer Genome Atlas (TCGA) database compared to normal brain tissue in Genotype-Tissue Expression (GTEx) database ( Figure 3D , Figure S11B , C, D, E, F, G, H). Interestingly, CNV pattern 4-specific TFs JUNB and FOS showed opposite expression with comparison to other CNV patterns, and they played different roles in different types of cancers ( Figure 3C , Figure S12A , B, C, D). JUNB and FOS were both upregulated in GBM, acute myelocytic leukemia (LAML), and pancreatic adenocarcinoma (PAAD), but downregulated in other malignancies, such as bladder urothelial carcinoma (BLCA), lung adenocarcinoma (LUAD), and ovarian serous cystadenocarcinoma (OV) ( Figure S12A , B, C, D). Besides, we applied these gene sets to survival analysis of TCGA GBM cohort. To our surprise, only the core gene set of CNV pattern 4 was negatively correlated with both overall survival (OS) and disease free survival (DFS) ( Figure 3E , Figure S13A , B). We then compared the expression of CNV pattern 4 core gene set between primary GBM and recurrent GBM. The results showed that JUNB, 1 1 ATF3, ACTN1, CEBPB, EGR1, and NFKBIA were significantly highly expressed in recurrent GBM, and they showed positively associated with each other (Figure S13C, D). As expected, these recurrence-related genes (RRGs) were negatively associated with DFS ( Figure 3F ).
GBM cells lacking typical CNVs possess properties of stem cell
Many published studies revealed that recurrence of GBM after surgery were often located at the peri-tumoral regions (P and N regions). Therefore, we wondered whether CNV 4 GBM cells in P and N regions have the ability of gliomagenesis.
Analysis of CNVs compositions of each GBM sample showed that more than 94%
GBM cells in the P and N regions of GBM-3 and GBM-4 belonged to CNV pattern 4 ( Figure 4A , Figure S14A ). In particular, 100% GBM cells in the N region of GBM-3 were clustered into CNV pattern 4 ( Figure 4A ). We then performed sphere culture of primary GBM cells derived from these samples, the results of which showed that GBM cells from C region, P region as well as N region could form GBM sphere and express stem cell markers CD133 ( Figure 4B ), indicating that these cells had the potential of tumorigenesis 22, 30-32 .
To characterize the properties of CNV 4 GBM cells in more details, we furtherly analyzed their sub-clusters. As shown in figure 4C , GBM cells of CNV 4 were divided into 9 sub-clusters. Interestingly, GO enrichment analysis of sub-clusters'
DEGs revealed that sub-cluster 3 cells were involved in neurogenesis, gliogenesis, and stem cell differentiation ( Figure 4D , Figure S14B ), and they were mainly located 1 2 in P regions (166/173) ( Figure 4E ). We noticed that GBM stem like-cell marker SOX2 was highly expressed in sub-cluster 3 ( Figure 4D ), and the results of IHC demonstrated that SOX2 positive and Nestin positive cells existed in both P and N regions ( Figure S15A ). On the other hand, some of the other sub-clusters' DEGs were enriched in the biological processes associated with angiogenesis and muscle structure development. These results brought to mind the GBM stem cell (GCS) and
vasculogenic mimicry that can be formed by CD133 positive GCS 33, 34 . We then evaluated the resemblance of sub-clusters to endothelial cell, pericyte, and other central nervous system cell types, including astrocyte, oligodendrocyte, oligodendrocyte progenitor cell (OPC), neuron, and neural progenitor cell (NPC) (Cell type specific gene sets were listed in Supplementary Table S3 ) 35, 36 . As expected, the sub-cluster 3 expressed markers of astrocyte, oligodendrocyte, OPC and NPC simultaneously (11.97%, 5.36%, 24.24%, 8.03%, respectively), while the other sub-clusters' DEGs overlapped with endothelial cell or pericyte marker genes in different extents (from 0% to 21.57% and from 0% to 23.44%, respectively) ( Figure   4F ). In addition, we established stemness score, endothelial cell score and pericyte score according to the average expression of corresponding maker genes to estimate the properties of CNV pattern 4 GBM cells. These three scores revealed continuums rather than separate distribution of stemness and differentiations towards endothelial cell or pericyte ( Figure S14C ). Furthermore, pseudotime analysis by Monocle algorithm drew the developmental trajectories of CNV pattern 4 GBM cells based on their transcriptomic similarities 37, 38 . Consistent with the former result, sub-cluster 3 1 3 cells were located at initial state and the other sub-clusters were distributed along later states ( Figure 4G , Figure S14D ). Collectively, these results revealed that some GBM cells lacking typical CNVs possessed properties of stem cell and might differentiate into endothelial cell or pericyte.
Sub-clusters of intracranial immune cells and PBMC from GBM patients show abnormal phenotypes
Finally, we turned to the analysis of intracranial immune cells, the largest proportion in GBM tissue samples. CNV analysis demonstrated that these cells had uniform expression pattern but no hallmarks of GBM cell ( Figure 5A ). Notably, sub-clusters 12 and 17 showed special phenotypes ( Figure 5B , Figure S16A ). Both sub-clusters expressed the marker genes of microglia/macrophage, CSF1R, CD14, CD68, AIF1, and HLA-DRB1 ( Figure 5B ). Meanwhile, sub-cluster 12 simultaneously showed high expression of EGFR, PTPRZ1, SOX2, SLC35E3, and MDM2, the known GBM-associated genes; while sub-cluster 17 were featured by the expression of proliferation markers, KIAA0101, BIRC5, MKI67, NUSAP1, and TOP2A ( Figure   5B ). Gene ontology (GO) enrichment analysis of their DEGs indicated that sub-cluster 12 were associated with nervous system development ( Figure 5C ), and sub-cluster 17 were enriched in the biological processes of cell cycle ( Figure 5D ).
However, when comparing to GBM cells, these cells exhibited the characteristics of immune cells ( Figure 5E , Figure S16B ).
Leukocyte-associated processes were matched in both sub-clusters 12 and 17 ( Figure   1 4 5E, Figure S16B ), so we wondered whether these cells came from peripheral blood.
Besides, to explore whether peculiar GBM cells outside C regions also exist in the circulation of GBM patients, PBMC samples from these four GBM patients before surgery were analyzed by scRNA-seq. Interestingly, a cluster of proliferative cell was discovered in the PBMC of GBM patients ( Figure 5F , G). However, we did not found cells expressing both monocyte markers and GBM-associated markers ( Figure S16D , E). These proliferative cells were composed of T cells and B cells, but not monocytes ( Figure 5F , Figure S16E ). When comparing to GBM cells, these cells also showed involvement in immune system-related processes ( Figure S16F ). To investigate whether these cells were specific to the PBMC of GBM patients, we additionally examined PBMC samples collected from three healthy volunteers and three non-tumoral patients (epilepsy patients) by scRNA-seq. Clusters of cells highly expressing proliferation markers were not found in the PBMC of healthy volunteers and epilepsy patients ( Figure S16G , H).
Proliferation is regarded as a hallmark of malignant cells. However, by comparing the DEGs of proliferative GBM cells and immune cells, as well as previously reported proliferative glioma cells 16, 19, 20 , we found that different kinds of cells shared a common signature of proliferation, BIRC5, RRM2, AURKB, NUSAP1, and TOP2A
( Figure 5H , Figure S16I , Supplementary Table S4 ).
Discussion
Recurrence is almost inevitable in GBM patients even after aggressive multimodal 1 5 therapies including surgery, radiotherapy, and chemotherapy 10 . Recently, targeted therapy and immunotherapy have been developed to eliminate the refractory GBM cells, yet the effects of which were far away for satisfaction [39] [40] [41] [42] [43] . It is worth noting that most characterizations about GBM focused on C region that will be removed during surgery, but recurrences often occur outside the C region, indicating the existence of GBM cells that diffusely invade P and N regions. Extensive investigations of primary GBM cells in C region have dissected GBM from genetic and epigenetic aspects thoroughly 6-8, 11, 13, 20, 44 . However, conclusions derived from these cells could be modestly generalized to GBM cells outside C regions as well as recurrent GBM cells, as many studies have revealed great differences between them, such as responses to irradiation, temozolomide, and lomustine 3, 4, 7, 11, 45 . On the other hand, many studies have showed that additional resection beyond total contrast-enhancing resection could favor patients' outcomes 14, 15 . Therefore, it is of vital prognostic and therapeutic significance to investigate the GBM cells in P and N regions directly to develop novel post-operative treatment for GBM patients.
Since the first isolation and characterization of GBM cells outside C region by Daniel L. Silbergeld and colleagues in 1997 46 , more and more investigators focused on this field and tried efforts to elucidate the features specific to these cells. However, previous studies reported diverse properties of GBM cells outside C regions compared to those in C region. For instance, Daniel L. Silbergeld found no difference in motility between GBM cells isolated from C region and P/N regions 46 , while some other studies demonstrated more invasive features of GBM cells in P/N regions than those 1 6 in C region 45, 47 . Similarly, some researchers showed that GBM cells derived from P/N regions proliferated faster than those in C region did 45, 46 , whereas some others observed opposite results 17, 48 . These seemingly contradictory results might be partially explained by the heterogeneity of GBM cells, which had been extensively revealed by multiomics studies 6-9, 13, 20 . Meanwhile, these results point out the fact that current understanding of GBM cells outside C region is incomplete. In this study, we applied scRNA-seq to GBM samples of C, P and N regions. We discovered peculiar GBM cells in P and N regions distinct from those in C region, characterized by CNVs. The characteristics of peculiar GBM cells in P and N regions have hardly been discussed before.
The origin of GBM cells remains unclear. Some studies proposed that GBM was most typical GBM cells, less CNVs were found in these peculiar GBM cells. Another study revealed that aneuploidy cells were found in only 68% and 32% of samples of C and P regions, respectively, and they made up 3 to 84% of all cells 4 . In this study, we identified four CNV patterns in twelve GBM samples. The CNV pattern 4 showed lower degree of CNVs than the other three patterns. Interestingly, more than 90% of CNV pattern 4 GBM cells were distributed in P and N regions of four GBM patients, while the other CNV patterns GBM cells were found mainly in the C region of particular patients, which was consistent with previous studies 17, 20 . Furthermore, pseudotime analysis revealed transitional trend from CNV pattern 4 to other CNV patterns. The homogeneous distribution and moderate CNV state of CNV pattern 4 GBM cells suggested the common mechanism of infiltration among highly heterogeneous GBM cells, and the possibility of CNV pattern 4 as the prodromal and transitional status of fully transformed malignant cells. It has been documented that recurrent GBM cells developed novel genetic variations compared to primary GBM cells, under the selective pressure of radiotherapy and chemotherapy 7, 11, 12, 53 .
However, the dynamic changes of CNVs occurrence and progression, as well as the underlying regulatory mechanism remain largely unknown. Further experiments are needed to shed light on the processes of CNVs development.
Although CNV is a pivotal mechanism employed by cancer cell to regulate gene expression, transcriptome is orchestrated by multiple factors. Only 40 to 60% of the amplified genes in cancer cells were founded parallel to corresponding RNA transcripts 54 . Therefore, the inferred CNVs based on RNA-sequencing contained 1 8
information of both CNVs and other regulatory mechanisms of transcriptome, and meanwhile omitted some CNVs inconsistent with their RNA transcripts. Our data revealed that GBM cells of different CNV patterns were also controlled by different transcriptional regulation networks. In particular, the core TFs-TCFs gene set of CNV pattern 4 was negatively correlated with both OS and PFS of GBM patients. Despite prominent heterogeneity, we figured out some common TFs among four CNV patterns, such as JUN and MYC, which were also identified as central TFs by recently published study using multiomics to construct kinase-TF centered network in HGG 29 .
These common TFs might play essential role in GBM cells. Typically, GBM cells can be classified into three molecular subtypes according to bulk transcriptomic profiles, the classical, mesenchymal, and proneural subtypes 6, 7 . To simplify this model, Li
Wang and colleagues focused on the glioma stem-like cells (GSCs) of mesenchymal, proneural, and classical subtypes (mGSC, pGSC, and cGSC, respectively) 55 . They discovered that cellular states of GSCs ranged from mesenchymal root to proneural terminal, between which were intermediate population. Interestingly, three TFs specific to this intermediate population, ATF3, JUNB, and JUN, were also found in the core TFs-TCFs gene set of CNV pattern 4, which further supports our hypothesis that CNV pattern 4 might be shared transitional state of heterogeneous GBM cells. We also noticed that ATF3 is a bidirectional switch regulating the treatment responses of GBM cells. On the one hand, ATF3 is involved in resistance to temozolomide (TMZ), cisplatin, and ultraviolet light 56, 57 , but on the other, it serves as a key mediator in proteasome inhibitor-induced GSC-selective apoptosis 58 . Besides, another two CNV 1 9 pattern 4-specific core TFs, FOS and JUNB, were proved to confer GBM cells with TMZ resistance 59 . These reports underscore the intrinsic resistance to chemotherapy of CNV pattern 4 GBM cells, as well as the necessity of more researches to overcome this obstacle.
Remarkably, sub-cluster of CNV pattern 4 GBM cells expressed CD133, and showed ability to form sphere, indicating the stem cell-like properties and potential of tumorigenesis. Consistently, SGM Piccirillo and colleagues showed that GBM cells isolated from P/N regions could form neoplasm in mouse model, although they had lower expression level of stem cell markers Nestin, SOX2, and Notch2 compared to those in C region 48 . Besides, CD133-positive and Nestin-positive invasive GBM cells were founded in murine models and they kept the ability of self-renewal 60, 61 . It has been demonstrated that CD133-positive glioblastoma stem cells (GSC) is the source of vasculogenic mimicry (VM) 33, 34 that leads to compromised effect of anti-angiogenesis therapy in GBM 62 . In this study, we found that sub-clusters of CNV pattern 4 GBM cells resembled endothelial cell and pericyte in different extents, which implied the possibility of CNV pattern 4 GBM cells participating in VM.
To our surprise, proliferative immune cells were discovered in GBM tissue, as well as the PBMC of GBM patients but healthy volunteers and epilepsy patients. Proliferative immune cells in GBM tissue and PBMC were macrophages and lymphocytes (T cells and B cells), respectively. Notably, proliferative T cells simultaneously expressed perforin and granzyme-related genes such as PRF1, GZMA, GZMB, GZMH, and GNLY, while proliferative B cells showed upregulated expression of 2 0
immunoglobulin-related genes such as IGKC, IGKV1-12, and JCHAIN, presenting the properties of plasm cell. These transcriptomic profiles suggested that they were highly responsive to GBM. Apart from refractory resistance to standard of care, GBM is notorious for being highly immunosuppressive both locally and systemically 63, 64 , which increases challenges to immunotherapy in GBM. Although making up less than 1% of PBMC, these proliferative immune cells represent the seeds of revolution against GBM, and propose a new way to dig out the potential of immune system in GBM treatment. On the other hand, since these peculiar immune cells were specific to the PBMC of GBM patients, they could be suitable targets for recurrence monitoring in addition to MRI that showed limited efficiency in differentiating tumor recurrence and pseudoprogression 65 . Therefore, the biological function and underpinning of these peculiar immune cells remained to be explored in more details.
Taken together, this study discovered peculiar GBM cells in P and N regions distinct from GBM cells in C region. First, these cells have fragmental but not typical CNVs of GBM cells. Second, these cells resemble GBM cells of typical CNVs at transcriptomic level in certain extent and have potential to transform into the cellular states of them. Third, sub-cluster of these cells possesses stem cell-like properties, and may participate in the process of vasculogenic mimicry. Finally, yet importantly, the core signature of transcriptional regulation network of these cells is negatively correlated with GBM patients' outcomes. Further, we characterized both local and systemic immune responses under the circumstance of GBM lesion. We discovered proliferative immune cells that were highly responsive to GBM in both GBM tissue 2 1 and PBMC. The peculiar CNV 4 GBM cells and peculiar proliferative immune cells from GBM patients identified by this study can be ideal targets for diagnosis, therapy and prognosis.
Materials and methods
Samples acquisition
This study was approved by the Ethics Committee of Nanfang Hospital. Written Supplementary Table S1 : Pathological diagnosis information of four GBM patients).
Hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) staining
HE and IHC staining assays were performed to examine the histological structure and the protein expression in GBM samples and normal brain tissue. These assays were performed as previously reported 66, 67 . Briefly, specimen slices were obtained from paraffin-embedded tissue blocks with a microtome (Leica, EG1150H, Wetlzar, Germany), deparaffinized and rehydrated. For HE staining, slices were immersed in hematoxylin and eosin sequentially. For IHC staining, slices were further processed, including antigen retrieval, blocking of endogenous peroxidase, primary antibody 2 2 incubation, secondary antibody incubation, and nuclear staining. Finally, the slices were sealed with mounting medium for imaging. Antibodies used in this study were listed in Supplementary Table S5 .
Primary culture of GBM cells and immunocytochemistry (ICC)
GBM samples were stored in ice and sent to the laboratory within one hour. 
CNV inference from scRNA-seq data
CNVs of putative GBM cells were evaluated according to transcriptomic information by moving average algorithm inferCNV 8, 19-21, 74, 75 . Briefly, all detected genes were sorted by their chromosomal location, and then the expression level of each gene in 2 6 each cells was calculated based on additional 100 neighbor genes (50 from upstream and 50 from downstream), which was set as a sliding window for each chromosome.
In this way, gene-specific expression patterns could be smoothed in certain extent, and thus the CNVs' effects on transcriptome become prominent. Considering the cell lineages of GBM belong to central nervous system, only oligodendrocytes were used as normal karyotype reference. Hierarchical clustering was performed by "fastcluster 1.1.25" to identify CNV patterns 76 .
Construction of TFs-TCFs-Targets regulatory network
Firstly, we obtained the gene lists of TFs TFs-TCFs interaction network and DETGs were used for construction of simplified TFs-TCFs-Targets regulatory network for each CNV pattern in Cytoscape software.
Availability of Data
scRNA-seq data of this study are available upon request on corresponding authors.
Statistics
The statistical analyses were performed in SPSS statistical software, version 21.0 (SPSS Inc., Chicago, IL, USA). Survival analysis of TCGA GBM cohort was performed in GEPIA2 platform, which employed Log-rank test for hypothesis test 73 .
Rank sum test was performed for recurrence-related genes (RRGs) comparison between primary GBM and recurrent GBM of China Glioma Genome Atlas database (http://www.cgga.org.cn/index.jsp) ( Figure S13C ). Spearmen correlation coefficient was calculated for RRGs ( Figure S13D ). Significance cut-off: *, P <0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001.
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